FORA Capital’s ImmunityBio IBRX Stock Holding History

FORA Capital’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$521K	Sell	59,509 -125,965	-68%	-$953K	0.04%	262
2026 Q1	$1.42M	Buy	+185,474	New	+$1.27M	0.1%	198

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FORA Capital's IBRX Position: Q2 2026 in Review

FORA Capital reduced its ImmunityBio (IBRX) stake by 68% in Q2 2026, selling an estimated $953K and leaving 59,509 shares worth $521K. The position accounts for 0.04% of the portfolio, ranked #262.

FORA Capital first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.42M in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

FORA Capital held 59,509 shares of ImmunityBio worth $521K as of Q2 2026.
FORA Capital sold 125,965 ImmunityBio shares in Q2 2026, an estimated $953K.
ImmunityBio made up 0.04% of FORA Capital's portfolio in Q2 2026, its #262 holding.
FORA Capital first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
FORA Capital's ImmunityBio position peaked at $1.42M in Q1 2026.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on FORA Capital's 13F filing for Q2 2026, filed 13 Aug 2026.